1. Home
  2. AMSF vs PRTA Comparison

AMSF vs PRTA Comparison

Compare AMSF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMERISAFE Inc.

AMSF

AMERISAFE Inc.

HOLD

Current Price

$29.12

Market Cap

584.3M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.76

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMSF
PRTA
Founded
1985
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
584.3M
526.7M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
AMSF
PRTA
Price
$29.12
$8.76
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$46.33
$19.00
AVG Volume (30 Days)
227.0K
536.4K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
8.61%
N/A
EPS Growth
N/A
N/A
EPS
1.21
0.26
Revenue
$317,252,000.00
$814,000.00
Revenue This Year
$8.45
$1,111.38
Revenue Next Year
$6.03
N/A
P/E Ratio
$24.57
$14.30
Revenue Growth
2.66
N/A
52 Week Low
$28.94
$7.40
52 Week High
$47.86
$11.80

Technical Indicators

Market Signals
Indicator
AMSF
PRTA
Relative Strength Index (RSI) 38.72 46.27
Support Level $29.46 $8.12
Resistance Level $32.11 $10.29
Average True Range (ATR) 0.93 0.37
MACD -0.23 0.01
Stochastic Oscillator 14.06 51.33

Price Performance

Historical Comparison
AMSF
PRTA

About AMSF AMERISAFE Inc.

AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: